StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)

Investment analysts at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and set a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.

Minerva Neurosciences Stock Down 3.0 %

Shares of Minerva Neurosciences stock opened at $2.26 on Friday. The firm has a market cap of $15.80 million, a price-to-earnings ratio of -5.14 and a beta of 0.11. Minerva Neurosciences has a 52-week low of $2.06 and a 52-week high of $13.49. The company’s 50-day simple moving average is $2.28 and its 200-day simple moving average is $2.70.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.